Table 3.

Inclusion criteria for Hearts in Rhythm Organization (HiRO) substudies with comprehensive data collection and longitudinal follow-up

HiRO Registry substudies	Inclusion criteria	Exclusion criteria
CASPER1	1.Unexplained cardiac arrest (UCA) requiring cardioversion or defibrillation at ≤ 60 y of age 2.Sudden death victim with negative autopsy and DNA available for molecular autopsy 3.Parents of an unexplained cardiac arrest survivor or sudden death victim before age 35, willing to provide a biobank sample for trio analysis	1.Coronary artery disease (any stenosis > 50%) 2.Reduced left ventricular function (LVEF < 50%) 3.Persistent resting QTc > 460 ms for males and 480 ms for females 4.Reversible cause of cardiac arrest such as marked hypokalemia (< 2.8 mmol/L) or drug overdose in sufficient gravity without other cause to explain the cardiac arrest 5.Haemodynamically stable sustained monomorphic ventricular tachycardia 6.Type 1 Brugada ECG with > 2 mm ST elevation in the anterior precordial/high leads
National ARVC Registry2	1.2010 Revised Task Force Criteria positive or borderline patients 2.Disease causing ARVC pathogenic mutation carriers meeting no additional TFC 3.Variants of uncertain significance carriers with at least 1 minor TFC 4.Age > 2 y 5.First-degree relatives of 2010 revised TFC-positive or TFC-borderline patients	1.Known condition that mimics ARVC (ie, sarcoidosis) 2.Dilated or hypertrophic cardiomyopathy not compatible with an ARVC genetic variant 3.Brugada syndrome not compatible with an ARVC variant 4.Diagnosis of other known inherited condition that predisposes to sudden death 5.Life expectancy < 1 y
National LQTS Registry	1.Gene-positive LQTS patients 2.Gene-negative LQTS patients with confirmed phenotypic diagnosis (Schwartz score ≥ 4) 3.Genotype- or phenotype-negative first-degree family members of genotype- and/or phenotype-positive LQTS patients	1.Genotype- and phenotype-negative LQTS patients without an affected family member
National Brugada Registry	1.Patients with a definite diagnosis of Brugada syndrome, defined as ST elevation with type 1 morphology > 2 mm in > 1 of the right precordial leads V1-V2 positioned in the 4th, 3rd, or 2nd intercostal spaces, either spontaneously or after provocation drug test with IV class 1 drugs or during fever 2.First-degree family members of those with a definite diagnosis of Brugada syndrome 3.Sudden death victims with a pathogenic variant in SCN5A leading to decreased Nav1.5 function identified on molecular autopsy	1.Patients with a type 2 Brugada pattern that does not convert to a type 1 morphology after a provocation drug challenge or in whom a provocation challenge is not performed

ARVC, arrhythmogenic right ventricular cardiomyopathy; CASPER, Cardiac Arrest Survivors with Preserved Ejection Fraction Registry; ECG, electrocardiogram; IV, intravenous; LQTS, long QT syndrome; LVEF, left ventricular ejection fraction; TFC, task force criteria.